תסמיני גמילה משימוש איאטרוגני באופיואידים ובנזודיאזפינים במטופלים קשים- סקירה שיטתית
תוצאים קליניים לאחר חוסר הצלחה בהורדת מינוני צפלוספורינים במבוגרים עם אי ספיקה כלייתית כרונית
שכיחות מחלות גלומרולריות ב-20 השנים האחרונות בערב הסעודית
ירידה בסיכון לסרטן הקיבה לאחר ארדיקציה של הליקובקטר פילורי בסוכרתיים הנוטלים מטפורמין
יעילות טיפול בסופוסבוויר/ לדיפסוויר בבני עשרה עם הפטיטיס C
Subscribe to Medic
The only Israeli drug index for medical professionals
Search all the drugs distributed in Israel
Antihistamine. Dimethindene Maleate 1 mg/ml. ORAL DROPS: 20 ml x 1 mg/ml (0.05
mg/drop). 20-40 drops 3 x dly. Child:
about 0.1 mg/kg bdy wt. 1 mth-1 yr:
3-10 drops 3 x dly, 1-3 yrs: 10-15 drops
3 x dly; 3-12 yrs: 15-20 drops 3x dly.
Prurit., allerg. conds.
Analgesic, Antipyretic, Opioid. Caffeine 50 mg, Codeine Phosphate 15 mg, Paracetamol 500 mg. CAPLETS: 12, 24. 1 capl. × 3-4 times/day. For severe pains - 2 capl. 3-4 times/day. Do not exceed a dosage of 8 capl. in 24 hrs. See lit.
For the relief of pain and coughs and for the reduction of fever accompanied by pain.
C/I: Hypersens. 1st & 3rd trim. of preg. Lact. Child. under 12 yrs. old. Adolesc. over 12 yrs. old and under 18 yrs. old after surg. remov. of their tonsils or adenoids. Concom. use with medic. contain. paracetamol /codeine. Pts. with respirat. depress. Pts. who are known as ultra-rapid metabolizer.
Antibacterial, Antifungal, Corticosteroid. Gramicidin 0.25 mg/g, Neomycin Sulphate 2.5 mg/g, Nystatin 100000 IU/g, Triamcinolone 1 mg/g. CREAM: 5, 15 g. Apply 2-3 x dly.
See lit.
Allerg. and infect. dermatit., eczema,
cutan. candidiasis, anogenital prurit.
C/I: T.B., herpes simplex, vaccinia,
varicella, lesions not suscept. to nystatin.
Antibacterial, Antifungal, Corticosteroid. Gramicidin 0.25 mg/g, Neomycin Sulphate 2.5 mg/g, Nystatin 100000 IU/g, Triamcinolone 1 mg/g. OINT.: 5, 15 g. Apply 2-3 x dly.
See lit.
Allerg. and infect. dermatit., eczema,
cutan. candidiasis, anogenital prurit.
C/I: T.B., herpes simplex, vaccinia,
varicella, lesions not suscept. to nystatin.
Quinolone. Ciprofloxacin (as hydrochloride) 500 mg. CAPS: 10 × 500mg. Upper & lower respir. tract infect.: 500-750mg 2 x dly.
UTI: 250-500mg 2 x dly. (in premenopaus.
women, 500 mg single dose may be used).
Genital tract infect.: Gonococ. urethritis
& cervicitis: 500mg as a single dose.
Epididymo-orchitis and pelvic inflamm.
Dis.: 500-750mg 2 x dly.
Infec. of the GI tract and intra-abdom.
infect., Diarrhoea caused by bacterial
pathogens include. Shigella spp. other
than Shigella dysenteriae type 1 and
empirical tmt. of severe travellers’
diarrhea, Diarrhoea caused by Shigella
dysenteriae type 1, Diarrhoea caused
by Vibrio cholera, Typhoid fever: 500mg x 2 dly.
Intra-abdom. infec. due to Gramnegative
bacteria: 500-750mg 2 x dly.
Infec. of the skin and soft tissue: 500-
750mg 2 x dly.
Bone & joint infec.: 500-750mg 2 x dly.
Neutropenic pts. with fever suspected
to be due to a bact. infec.
Ciprofloxacin should be co-admin. with
appropriate antibact. agent(s) in
accordance to official guidance: 500-
750mg 2 x dly over the entire period of
neutropenia.
Prophylax. of invas. infec. due to
Neisseria meningitides: 500 mg as a
single dose.
Inhal. anthrax post-exposure prophylax. and curative tmt. for persons able to receive tmt. by oral route when clinical. appropriate. Drug admin. should begin as soon as possible after suspected or confirmed exposure: 500mg 2 x dly. See lit.
Ped. pts.: CF: 20 mg/kg bdy. wt. twice dly. with a max.of 750 mg/dose.
Complic. UTI and pyelonephritis: 10
mg/kg bdy. wt. twice dly. to 20 mg/kg
bdy. wt. twice dly. with a max. of 750
mg/dose.
Inhal. anthrax post-exposure prophylax. & curative tmt. for persons able to receive tmt. by oral route when clinical. appropr. Drug admin. should begin as soon as possible after suspect. or confirmed exposure: 10 mg/kg bdy. wt. twice dly. to 15 mg/kg bdy. wt. twice dly. with a max.of 500 mg/ dose.
Other severe infec.: 20 mg/kg bdy. wt.
twice dly. with a max. of 750 mg/dose.
See lit.
Elderl.: should receive a dose selected
accord.to the sever.of the infec. and the
pts. CrCl. Pts. with renal.& hep. impair.: see lit.
Adult.: Broad spectr. antibiotic for infec.
caused by ciprofloxacin sensit.
pathogens.
Child., adolesc.: Broncho-pulmon. infec.
in CF caused by Pseudomonas a.
Complic. UTI, pyelonephritis.
Inhal. anthrax (post-exposure prophylax. & curative tmt.). May also be used to treat
severe infec. in child.& adolesc. when
there is no other alternative.
Tmt. should be initiat.only by physicians
who are experienc. in the tmt. of CF and/
or severe infec. in childr., adolesc.
C/I: Hypersens. to ciprofloxacin or other
quinolones.
Concom. admin. with Tizanidine. See lit.
Analgesic, Antipyretic. Paracetamol 500 mg. TABS: 20 x 500 mg. 1-2 tabs. every 4-6
hrs. Not to exceed 8 tabs/day. Child:
6-12 yrs: 1/2 adult dose. Not to exceed
4 doses in 24 hrs.
CAPLETS: 14, 21. (blister pack), 50 x 500
mg.
1-2 caplets every 4-6 hrs. Not to
exceed 8 caplets/day.
Pain, fever.
Analgesic, Antihistamine, Antipyretic, Antitussive, Decongestant. Chlorpheniramine Maleate 2 mg, Dextromethorphan HBr 10 mg, Paracetamol 500 mg, Pseudoephedrine HCl 25 mg. CAPLET.: 10, 16, 20. Adult. & child. over 12
yrs. of age: 1-2 capl. before bdtm. See
Lit.
For the symptom.relief of cold, cough,
nasal congest. accompan. by fever and
pain, for tmt. at night.
C/I: Hypersens. to the act. ingred.or
other antihistamin., decong.
Pregn., lact. Concom. use with: MAOIs, or
within 14 d. of stop. tmt. with them),
SSRIs, decongestant.; addit. meds. that
contain antihistamin., other cough &cold
meds., β-block.; relief of chron. cough;
Concom. use with other paracetamol
contain. meds.; Pts. who suffer from the
follow. dis. or cond.: severe hypertens.,
heart/vascular dis., severe hep./ren. dis.,
hyperthyroidism, glaucoma, prostate
gland dis., a cough accompan. by excess.
phlegm or that lasts long, dispnea,
asthma, pulmon. dis., diabetes. See lit.
Antifungal. Clotrimazole 1%. CREAM: 30 g. Apply thin layer to affect.
area, rub in gently 2-3 x dly as foll:
Dermatomycos: 3-4 weeks; erythrosma:
2-4 wks; pityrias versicolor: 1-3 wks;
candida vulv./balanit: 1-2 wks. Cont. till
2 wks. aft. disappear. sympts.
Skin infects. caused by dermatophytes/
candida.
C/I: Hypersens. to clotrimazole,
cetylstearyl alcohol. See lit.
CCB, Local Anesthetic. Lidocaine HCl 1.5%, Nifedipine 0.3%. RECTAL CR.: 30g. Should be applied twice dly. for at least 3 wks. See lit.
Tmt. of anal fissures and proctolog. general. associate. with anal sphincter hypertonia.
C/I: Hypersens. to the active ingred., partic. to Lidocaine (& other local anesthet. with a similar amidic type structure). Presumed or ascertained preg. & lact.
Monoclonal Antibody. Rituximab 100 mg, 500 mg. VIAL (concentr. for sol. for infus.): 1×50ml, 2×10ml. Dosage must be adjust. individ. for each pt.
CLL: In comb. with chemother. is indic. for the tmt. of pts. with previos. untreated and relapsed/refract. CLL. Only limited data are available on effic. and safety for pts. previous. treated with MABs include. rituximab or pts. refract. to prev. rituximab plus chemother.
Granulomatosis with polyangiitis and microscopic polyangiitis.
In combin. with glucocorticoids, is indic. for the tmt. of adult pts. with granulomatosis with polyangiitis (GPA) (Wegener’s Granulomatosis (WG)) & microscopic polyangiitis (MPA).
C/I: For use in CLL: Hypersens., Active, sev. infec., Pts. in a sev. immunocomprom. state. For use in granulomatosis with polyangiitis and microscopic polyangiitis: Hypersens. to the active subst./murine proteins., Active, sev. infec., Pts. in a sev. immunocomprom. state., Severe HF (New York Heart Association Class IV) or sev., uncontrol. cardiac dis.
Muscle relaxant. Rocuronium Bromide 10 mg/ml. Vial (sol. for. inj): 10×5ml. Dosage must be adjust. individ.
Indicated in adult & paed. pts. (from term neonates - adolescents [0 to <18 years]) as an adjunct to general anaesthesia to facilitate tracheal intubate. during routine sequence induct. and to provide skeletal muscle relax. during surg.
In adults it is also indica. to facilitate tracheal intubation during rapid sequence induct. and as an adjunct in the intens. care unit (ICU) to facilitate intubat. and mechanic. ventilation.
C/I: Hypersens.
Cyclin-Dependent Kinase Inhibitor. Abemaciclib 50, 100, 150, 200 mg. F.C TABS.: 14. When given with, the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, and 29; and once mnthly. Pre/perimenopausal women treated with the comb. of Abemaciclib plus fulvestrant should be treated with a gonadotropin-releas. hormone agonist accord. to current clinic. practice standards.
When used as monotherapy, the recommended dose is 200 mg×2/d.
Cont. tmt. until dis. progres. or unaccept. toxic. Abemaciclib may be taken with / without food. For dose modif. for ADR's see lit. See lit.
In comb. with a non-steroid. aromatase inhib. as initial endocr.-based ther. for the tmt. of postmenopaus. women with hormone receptor (HR)-posit., human epiderm. growth factor receptor 2 (HER2)-neg. advanc. or metastat. breast canc.
In comb. with fulvestrant for the tmt. of women with hormone receptor (HR)-positive, human epiderm. growth fact. receptor 2 (HER2)-neg. advance. or metast. breast cancer with dis. progress. follow. endocr. ther.
As monother. for the tmt. of adult pts. with HR-posit., HER2-neg. advanc. or metastat. breast cancer with dis. progres. follow. endocr. ther. in the metastat. setting and prior chemother. in the metast. setting includ. taxane in adjuv. or metastat. setting.
Verzenio should not be used in women after prior tmt. with cyclin-depend. kinases 4 and 6 (CDK4 and CDK6) inhib.
C/I: Hypersens.
Janus Kinase Inhibitor (JAKs). Baricitinib 2 mg, 4 mg. F.C. TABS.: 28. 4 mg ×1/d. A dose of 2 mg×1/d. is approp. for pts. such as those aged ≥ 75 yrs. and may be approp. for pts. with a history of chron. or recur. infect. A dose of 2 mg×1/d may also be consid. for pts. who have achieved sustain. control of dis. active. with 4 mg×1/d and are eligible for dose tapering. Tmt. should not be initiat. in pts. with an absolute lymphocyte count (ALC) less than 0.5 x 109 cells/L, an absolute neutrophil count (ANC) less than 1 x 109 cells/L, or who have a haemoglobin value less than 8 g/dL. Tmt. may be initiat. once values have improv. above these limits. See lit.
Tmt. of moder.- severe active RA in adult pts. who have responded inadequate. to, or who are intolerant to one or more dis.-modif. anti-rheum. drugs. May be used as monother. or in comb. with methotrexate.
C/I: Hypersens. Preg.
Antihemorrhagics. Human Coagulation Factor VIII 250, 500, 1000, 2000 IU. VIAL (pwdr. & solvent for sol. for inj.): 1× 250,500,1000,2000 IU. The dose & duration of the substitute. ther. depend on the sever. of the factor VIII defic., on the loca. and extent of the bleed. and on the pt's. clinical condition. See lit.
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups.
C/I: Hypersens. Known allerg. react. to mouse or hamster proteins.
Anticholinergic agent. Atropine Sulphate 1 mg/ml. AMP. (sol. for IM, IV inj.): 5×1ml. Pre-anesthet. med.: Adults: 0.3-0.6 mg by IV inj. immed. before the anesthes. induct. or by IM inj. 30-60 min. before the induc.
Child.: 0.02 mg/kg (max. dose 0.6 mg).
Tmt. of sinus bradycard.: 0.3 and 1.0 mg IV.
Antidote in poison. by organophosphorus:
Adult.: 2 mg (IM or IV, taking into account the sever. of the poison.) every 5-10 min., until the skin becomes red and dry, the pupils dilate and tachycard. appears.
Child.: The 0.02 mg/kg.
Preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. Treatment of sinus bradycardia, particularly if complicated by hypotension.
Antidote in poisoning by organophosphorus.
C/I: Hypersens. Clos. ang. glauc., esophag. reflux, pyloric stenosis, GI obstruct., ulcerat. colit., prostat. hypertrophy, paralytic ileus, intest. atony.
